FDA grants orphan drug status to Papillon Therapeutics’ PPL-001

PPL-001 is a gene-corrected CD34+ hematopoietic stem and progenitor cell (HSPC) therapy. Credit: PublicDomainPictures from Pixabay.



  • Papillon